Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes by Thota, Sreekanth et al.
Introduction
The success of cisplatin and related platinum complexes as 
anticancer agents has stimulated a search for other active 
transition metal complexes, and ruthenium in particular has 
attracted research1. Metal complexes of ruthenium contain-
ing nitrogen and oxygen donor ligands are found to be effec-
tive catalysts for oxidation, reduction, hydrolysis, and other 
organic transformations2. The coordination environment 
around ruthenium plays a key role in stabilizing its different 
oxidation states and hence dictates the redox properties of 
the control atoms3,4.
Ruthenium compounds are regarded as promising alter-
natives to platinum compounds, and offer many approaches 
to innovative metallopharmaceuticals. The compounds are 
known to be stable and have predictable structures both in 
the solid state and in solution. The tuning of ligand affini-
ties is accompanied by a steadily increasing knowledge of 
the biological effects of ruthenium compounds1,5. The 
first systematic investigation of ruthenium compounds 
and their antitumor property was done at the beginning 
of the 1980s with the  compounds fac-[RuCl
3
(NH
3
)
3
] and 
 cis-[RuCl
2
(NH
3
)
4
]Cl6,  preceded by the discovery in the 1970s 
that ruthenium red possesses antitumor properties7,8. Since 
then, compounds such as trans-(IndH)[Ru(ind)
2
Cl
4
] (Ind = 
indazole), mer-[Ru(terpy)Cl
3
] (terpy = 2,2’-terpyridine)9–11, 
[Ru(dmso)
4
Cl
2
] (dmso = dimethyl sulfoxide)12, ImH[Ru(im)
Cl
5
]13, ImH[Ru(im)
2
-Cl
4
]14, and ImH[Ru(im)(dmso)Cl
4
]15 
(NAMI-A) (im = imidazole) have also become well-known 
antitumor agents.
Although the mechanism of action of ruthenium com-
pounds is not fully understood, it is thought that, for certain 
species, it is similar to that of platinum drugs16,17. NAMI-A 
has high selectivity for solid tumor metastasis and low host 
toxicity at pharmacologically active doses18, and it was the 
first ruthenium compound to enter clinical trials19. It has a 
remarkably low general toxicity20,21 and shows marked effi-
cacy against metastases22,23. It does not affect primary tumor 
growth24,25 and does not exhibit cytotoxicity against tumor 
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abstract
A series of mononuclear Ru(II) complexes of the type [Ru(S)2(K)]
2+, where S = 1,10-phenanthroline/2,2’-bipyridine 
and K = 4-OH-btsz, 4-CH3-btsz, 3,4-di-OCH3-btsz, 4-OH-binh, 4-CH3-binh, 3,4-di-OCH3-binh, were prepared and 
characterized by elemental analysis, FTIR, 1H-NMR, and mass spectroscopy. The complexes displayed metal–ligand 
charge transfer (MLCT) transitions in the visible region. These ligands formed bidentate octahedral ruthenium 
complexes. The title complexes were evaluated for their in vivo anticancer activity against a transplantable murine 
tumor cell line, Ehrlisch’s ascites carcinoma (EAC), and in vitro cytotoxic activity against human cancer cell lines 
Molt 4/C8 and CEM and murine tumor cell line L1210. The ruthenium complexes showed promising biological 
activity especially in decreasing tumor volume and viable ascites cell counts. Treatment with these complexes 
prolonged the life span of mice bearing EAC tumors by 10–52%. In vitro evaluation of these ruthenium complexes 
revealed cytotoxic activity from 0.21 to 24 µM against Molt 4/C8, 0.16 to 19 µM aginst CEM, and 0.75 to 32 µM 
against L1210.
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cells in vitro. A related ruthenium(III) compound, indazolium 
trans[tetrachlorobis (1H-indazole) ruthenate(III)], KP101926, 
has also entered clinical trials, since it was found to exhibit 
antiproliferative activity in vitro in human colon carcinoma 
cell lines27.
In comparing the general toxicity of ruthenium com-
pounds with platinum drugs, ruthenium has lower toxic-
ity, which has been attributed to the ability of ruthenium 
compounds to specifically accumulate in cancer tissues. The 
higher specificity of these compounds for their targets may 
be linked to selective uptake by the tumor compared with 
healthy tissue28,29 and selective activation by reduction to 
cytotoxic species within the tumor30.
Ruthenium compounds with bidentate ligands show 
intercalation properties with DNA31. The Ru(II) com-
pounds are kinetically more reactive than Ru(III)32. We have 
reported that Ru(II) compounds bearing thiosemicarbazides, 
8- hydroxyquinolines, and 4-substituted thiopicolinanalides 
have in vivo anticancer and in vitro antibacterial activity33–35. 
Recently, we have reported that Ru(II) compounds bearing 
isatin thiosemicarbazones and chloro-fluoro-phenyl imino 
methyl phenol have in vivo anticancer and in vitro cytotoxic 
activity36. In this work, we describe the synthesis and char-
acterization of some ruthenium complexes, their in vitro 
cytotoxic activity against human cancer cell lines Molt 4/C
8
 
and CEM and murine tumor cell line L1210, and their in vivo 
anticancer activity against transplantable murine tumor cell 
line EAC (Ehrlisch’s ascites carcinoma).
Materials and methods
Chemistry
AR grade solvents were obtained from S.D. Fine-Chem, 
Mumbai, and E. Merck, Mumbai. Puriss grade reagents were 
obtained from Fluka and E. Merck.
Hydrated ruthenium trichloride was purchased from Loba 
Chemie, Mumbai, and used as received. Ultraviolet (UV)-
visible spectra were recorded on a Jasco spectrophotometer. 
Fourier transform infrared (FTIR) spectra were recorded in 
KBr powder on a Jasco V410 FTIR spectrometer by the dif-
fuse reflectance technique. 1H/13C-nuclear magnetic reso-
nance (NMR) spectra were measured in CDCl
3
 and dimethyl 
 sulfoxide (DMSO)-d
6
 on Bruker Ultraspec 500 MHz/AMX 
400 MHz/300 MHz spectrometers. The reported chemical 
shifts were against that of tetramethylsilane (TMS). Fast 
atom bombardment (FAB) mass spectra were recorded on 
a Jeol JMS600 spectrometer with meta-nitrobenzylalcohol 
(mNBA) matrix. Substituted thiosemicarbazones were pre-
pared according to the literature method.
General procedure for preparing substituted benzyl 
thiosemicarbazones (r-btsz)
A mixture of substituted benzaldehyde (1 mmol) and 
 thiosemicarbazide (1 mmol) in 100 mL of ethanol was refluxed 
for 3 h and left overnight. The solid that separated was filtered 
and dried. The crude solid was purified by recrystallization 
from alcohol to give crystals.
4-OH-btsz Yield 56%, m.p. 224–225°C (lit., 226°C). IR 
(KBr) cm−1: 3469–3320 (NH
2
 and NH), 3200–2700 (O-H), 3133 
(C-H), 1610 (N-H), 1328 (C=S). Calcd. for C
8
H
9
N
3
OS: C, 49.21; 
H, 4.64; N, 21.52. Found C, 49.20; H, 4.62; N, 21.28%. λ
max
 nm 
(MeOH): 242, 321, 398. 1H NMR (DMSO-d
6
): δ = 12.6 (1H, s), 
11.24 (1H, s), 8.07 (1H, s), 7.99 (1H, s), 7.89 (1H, s, -OH), 7.73 
(2H, d, J = 8.6 Hz), 6.95 (2H, d, J = 8.6 Hz).
4-CH
3
-btsz Yield 79%, m.p. 160–162°C (lit., 160–161°C). 
IR (KBr) cm−1: 3416–3321 (NH
2
 and NH), 3151 (C-H), 1615 
(N-H), 1325 (C=S). Calcd. for C
9
H
11
N
3
S: C, 55.93; H, 5.74; 
N,21.74. Found C, 55.87; H, 5.62; N, 21.53%. λ
max
 nm (MeOH): 
234, 325, 389. 1H NMR (DMSO-d
6
): δ = 11.41 (1H, s), 8.10 (1H, 
s), 7.98 (1H, s), 7.78 (1H, s), 7.71 (2H, d, J = 8.9 Hz), 6.98 (2H, 
d, J = 8.9 Hz), 1.64 (3H, s, CH
3
).
3,4-di-OCH
3
-btsz Yield 56%, m.p. 194–195°C (lit., 195°C). 
IR (KBr) cm−1: 3406–3320 (NH
2
 and NH), 3133 (C-H), 1610 
(N-H), 1332 (C=S). Calcd. for C
10
H
13
N
3
O
2
S: C, 50.19; H, 5.47; 
N,17.56. Found C, 50.21; H, 5.61; N, 17.43%. λ
max
 nm (MeOH): 
239, 331, 395. 1H NMR (DMSO-d
6
): δ = 11.32 (1H, s), 8.16 (1H, 
s), 8.02 (1H, s) 7.97 (1H, s) 7.51 (1H, d), 7.13 (1H, dd, J = 8.6 Hz), 
6.94 (1H, d, J = 8.3 Hz), 3.81 (3H, s, -OCH
3
), 3.78 (3H, 
s, -OCH
3
).
General procedure for preparing substituted benzyl 
isonicotinyl hydrazones (r-binh)
A mixture of substituted benzaldehyde (1 mmol) and isoni-
azid (1 mmol) in 100 mL of ethanol was refluxed for 3 h and 
left overnight. The solid that separated was filtered and dried. 
The crude solid was purified by recrystallization from alcohol 
to give crystals.
4-OH-binh Yield 65%, m.p. 287–288°C (lit., 287°C). IR 
(KBr) cm−1: 3328(NH), 3180–2750 (O-H) 3148 (C-H),1683 
(C=O), 1615 (N-H). Calcd. for C
13
H
11
N
3
O
2
: C, 60.22; H, 5.05; 
N,16.21. Found C, 60.17; H, 5.03; N, 16.07%. λ
max
 nm (MeOH): 
233, 315, 391. 1H NMR (DMSO-d
6
): δ = 11.52 (1H, s), 11.27 
(1H, s), 8.03 (1H, s, O-H), 7.78 (2H, d, J = 8.7 Hz), 6.95 (2H, d, 
J = 8.7 Hz), 7.76 (2H, d, J = 8.4 Hz), 6.87 (2H, d, J = 8.4 Hz).
Preparation of cis-[bis(S)dichlororuthenium(II)] 
 cis-[Ru(S)2Cl2]
37 (where S = 2,2’-bipyridine/1, 
10-phenanthroline)
RuCl
3
.H
2
O, 1g (2.5 mmol) and ligand S (5 mmol) were refluxed 
in 50 mL dimethylformamide (DMF) for 3 h under a nitrogen 
atmosphere. The reddish brown solution slowly turned pur-
ple and the product precipitated in the reaction mixture. The 
solution was cooled overnight at 0°C. A fine microcrystalline 
mass was filtered off. The residue was repeatedly washed with 
30% LiCl solution and finally recrystallized from the same. 
The product was dried and stored in a vacuum desiccator 
over P
2
O
5
 for further use (yield 75%).
General procedure for preparing -[Ru(S)2(K)Cl2] (where 
S = 1,10-phenanthroline (Ru 1)/2,2’-bipyridne (Ru 2); 
where K = 4-OH-btsz, 4-CH3-btsz, 3,4-di-OCH3-btsz, 
4-OH-binh, 4-CH3-binh, 3,4-di-OCH3-binh)
To the black microcrystalline cis-bis(S)dichlororuthenium(II) 
{cis-Ru(S)
2
Cl
2
} (2 mmol), excess of ligand (r-btsz and r-binh) 
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Activities of mononuclear Ru(II) complexes  515
(2.5 mmol) was added and refluxed in ethanol under a nitro-
gen atmosphere. The initial colored solution slowly changed 
to brownish orange at the end of the reaction, which was 
verified by TLC on silica plates. Then the excess of ethanol 
was distilled off and to the remaining solution was added 
silica gel (60–120 mesh). The product was purified by column 
chromatography using silica gel as the stationary phase and 
chloroform–methanol as the mobile phase.
Ru 1 46%, black crystals, IR (KBr) cm−1: 3402–3329 (NH
2
 
& N-H), 3210–2700 (O-H) 3036 (C-H), 1611 (N-H), 1328 (C=S). 
Calcd. for C
32
H
25
Cl
2
N
7
ORuS: C, 52.81; H, 3.43; N, 13.48. Found 
C, 52.26; H, 3.39; N, 13.32%. 1H NMR (DMSO-d
6
): δ ppm: 
10.02 (d, J = 5.1 Hz, 1H), 9.03 (s, 1H), 8.91 (d, J = 4.9 Hz, 1H), 
8.84 (t, J = 8.6 Hz, 2H), 8.63 (d, J = 8.4 Hz, 1H), 8.49 (d, J = 8.4 
Hz, 1H), 8.34–8.20 (m, 6H), 8.15–8.08 (m, 2H), 7.91 (d, J = 5.0 
Hz, 1H), 7.81–7.75 (m, 2H), 7.68–7.64 (s, 1H, O-H), 7.49–7.45 
(m, 1H), 6.91 (s, 2H, br, NH
2
), 6.73 (d, J = 14.6 Hz, 2H), 6.13 (s, 
1H). FAB-MS (mNBA): 727 [Ru(phen)
2
 (4-OH-btsz)]2+(Cl
2
)−; 
656 [Ru(phen)
2
 (4-OH-btsz)]2+; 475 [Ru(phen) (4-OH-btsz)]2+; 
462 [Ru(phen)
2
].
Ru 2 42%, black crystals, IR (KBr) cm−1: 3401–3238 (NH
2
 
& N-H), 3200–2700 (O-H) 3041 (C-H), 1621 (N-H), 1344 (C=S). 
Calcd. for C
28
H
25
Cl
2
N
7
ORuS: C, 49.48; H, 3.68; N, 14.43. Found 
C, 49.24; H, 3.59; N, 14.32%. 1H NMR (DMSO-d
6
): δ ppm: 10. 
(d, J = 4.9 Hz, 1H), 9.15 (s, 1H), 8.90 (d, J = 5.0 Hz, 1H), 8.72–8.42 
(m, 5H), 8.12–7.98 (m, 2H), 7.82–7.53 (m, 3H), 7.45–7.32 (m, 
2H), 7.22–7.16 (m, 1H), 7.09–6.99 (m, 2H), 6.92–6.72 (m, 3H), 
6.61 (s, 2H, br, NH
2
), 6.34–6.13 (m, 2H). FAB-MS (mNBA): 679 
[Ru(bpy)
2
 (4-OH-btsz)]2+(Cl
2
)−; 608 [Ru(bpy)
2
 (4-OH-btsz)]2+; 
452 [Ru(bpy) (4-OH-btsz)]2+; 413 [Ru(bpy)
2
].
Ru 3 44%, black crystals, IR (KBr) cm−1: 3318 (N-H), 
3200–2700 (O-H), 3041 (C-H), 1601 (N-H), 1681 (C=O). Calcd. 
for C
37
H
27
Cl
2
N
7
O
2
Ru: C, 57.43; H, 3.49; N, 12.67. Found C, 
57.26; H, 3.34; N, 12.32%. 1H NMR (DMSO-d
6
): δ ppm: 10.01 
(d, J = 5.1 Hz, 1H), 9.02 (s, 1H), 8.87 (d, J = 5.6 Hz, 1H),8.64 
(d, J = 8.3 Hz, 1H), 8.46 (d, J = 8.6 Hz, 1H), 8.37–8.19 (m, 6H), 
8.13–8.07 (m, 2H), 7.93 (d, J = 5.1 Hz, 2H), 7.84–7.78 (m, 2H), 
7.64–7.60 (s, 1H, O-H), 7.46–7.43 (m, 2H), 7.38–7.32 (m, 2H), 
6.93 (s, 2H, br, NH
2
), 6.77 (d, J = 15.2 Hz, 2H), 6.11 (s, 1H). 
FAB-MS (mNBA): 773 [Ru(phen)
2
 (4-OH-binh)]2+(Cl
2
)−; 702 
[Ru(phen)
2
 (4-OH-binh)]2+; 521 [Ru(phen) (4-OH-binh)]2+; 
462 [Ru(phen)
2
].
Ru 4 44%, black crystals, IR (KBr) cm−1: 3312 (N-H), 
 3200–2700 (O-H), 3041 (C-H), 1615 (N-H), 1675 (C=O). Calcd. 
for C
33
H
27
Cl
2
N
7
O
2
Ru: C, 54.62; H, 3.72; N, 13.52. Found C, 
53.89; H, 3.55; N, 13.28%. 1H NMR (DMSO-d
6
): δ ppm: 9.98. (d, 
J = 4.9 Hz, 1H), 9.18 (s, 1H), 8.91 (d, J = 5.3 Hz, 1H), 8.74–8.44 
(m, 5H), 8.11–7.97 (m, 2H), 7.93–7.89 (m, 2H), 7.80–7.51 (m, 
3H), 7.46–7.22 (m, 2H), 7.21–7.15 (s,1H, O-H), 7.10–7.01 (m, 
2H), 6.94–6.72 (m, 3H), 6.63 (s, 2H, br, NH
2
), 6.36–6.15 (m, 
2H). FAB-MS (mNBA): 725 [Ru(bpy)
2
 (4-OH-binh)]2+(Cl
2
)−; 
654 [Ru(bpy)
2
 (4-OH-binh)]2+; 498 [Ru(bpy) (4-OH-binh)]2+; 
413 [Ru(bpy)
2
].
Ru 5 44%, black crystals, IR (KBr) cm−1: 3414–3224 
(NH
2
 & N-H), 3032 (C-H), 1632 (N-H), 1331 (C=S). Calcd. for 
C
33
H
27
Cl
2
N
7
RuS: C, 54.62; H, 3.72; N, 13.52. Found C, 53.26; 
H, 3.72, N, 14.47%. 1H NMR (DMSO-d
6
): δ ppm: 10.15–10.04 
(m, 2H), 9.41 (s, 1H), 8.87–8.83 (m, 2H), 8.71 (s, 1H, br), 
8.53–8.51 (m, 1H), 8.46–8.34 (d, J = 5.7 Hz, 3H), 8.31–8.24 (m, 
4H), 8.01 (s, 2H, br, NH
2
), 7.91–7.85 (m, 4H), 7.59–7.45 (dd, 
1H, J = 8.2, 8.1 Hz), 7.51–7.42 (m, 2H), 7.23 (d, J = 8.3 Hz, 2H, 
br), 6.95 (d, 1H, J = 8.5 Hz), 6.13 (s, 1H). FAB-MS (mNBA): 
725 [Ru(phen)
2
 (4-CH
3
-btsz)]2+(Cl
2
)−; 654 [Ru(phen)
2
 (4-CH
3
-
btsz)]2+; 474 [Ru(phen) (4-CH
3
-btsz)]2+; 462 [Ru(phen)
2
].
Ru 6 44%, black crystals, IR (KBr) cm−1: 3409–3219 
(NH
2
 & N-H), 3035 (C-H), 1615 (N-H), 1327 (C=S). Calcd. for 
C
29
H
27
Cl
2
N
7
RuS: C, 51.41; H, 3.98; N, 14.47. Found C, 50.98; H, 
3.79; N, 14.35%. 1H NMR (DMSO-d
6
): δ ppm: 10.01 (m, 1H), 
8.82–8.76 (m, 2H), 8.70 (d, 1H, J = 5.6 Hz), 8.61 (d, 1H, J = 8.0 Hz), 
8.43 (d, 1H, J = 8.0 Hz), 8.06–8.00 (m, 3H, 7.79–7.73 (m, 2H), 
7.65–7.59 (m, 2H), 7.46 (d, 1H, J = 5.6 Hz), 7.31–7.22 (m, 3H), 
7.19–7.16 (mt, 3H, J = 12.0 Hz ), 6.97 (d, 2H, J = 12.0 Hz ), 
6.22 (s, 2H, br, NH
2
), 1.61(s, 3H, -CH
3
) FAB-MS (mNBA): 677 
[Ru(bpy)
2
 (4-CH
3
-btsz)]2+(Cl
2
)−; 606 [Ru(bpy)
2
 (4-CH
3
-btsz)]2+; 
452 [Ru(bpy) (4-CH
3
-btsz)]2+; 413 [Ru(bpy)
2
].
Ru 9 46%, black crystals, IR (KBr) cm−1: 3418–3226 
(NH
2
 & N-H), 3042 (C-H), 1608 (N-H), 1339 (C=S). Calcd. 
for C
34
H
29
Cl
2
N
7
O
2
RuS: C, 52.91; H, 3.76; N, 12.71. Found C, 
52.87; H, 3.68; N, 12.42%. 1H NMR (DMSO-d
6
): δ ppm: 10.09 
(d, J = 5.2 Hz, 1H), 8.98 (d, J = 5.6 Hz, 1H), 8.80 (t, J = 8.8 Hz, 
2H), 8.68 (d, J = 8.6 Hz, 1H), 8.51 (d, J = 8.6 Hz, 1H), 8.40–8.20 
(m, 6H), 8.11–8.03 (m, 2H), 7.88 (d, J = 5.0 Hz, 1H), 7.83–7.77 
(m, 2H), 7.67–7.63 (m, 1H), 7.46–7.42 (m, 1H), 6.98 (s, 2H, 
br, NH
2
), 6.75 (d, J = 14.9 Hz, 2H), 3.68 (s, 3H, -OCH
3
), 3.62 
(s, 3H, -OCH
3
), FAB-MS (mNBA): 771 [Ru(phen)
2
 (3,4-di-
OCH
3
-btsz)]2+(Cl
2
)−; 700 [Ru(phen)
2
 (3,4-di-OCH
3
-btsz)]2+; 
521 [Ru(phen) (3,4-di-OCH
3
-btsz)]2+; 461 [Ru(phen)
2
].
Ru 10 43%, black crystals, IR (KBr) cm−1: 3406–3217 
(NH
2
 & N-H), 3025 (C-H), 1612 (N-H), 1322 (C=S). Calcd. for 
C
30
H
29
Cl
2
N
7
O
2
RuS: C, 49.79; H, 4.01; N, 13.55. Found C, 49.56; 
H, 3.95; N, 13.42%. 1H NMR (DMSO-d
6
): δ ppm: 10.02 (d, J = 
5.0 Hz, 1H), 8.73–8.72 (d, J = 5.4 Hz, 1H,), 8.63–8.41 (m, 5H), 
8.10–8.03 (m, 3H), 7.88–7.70 (m, 6H), 7.46 (d, J = 4.9 Hz, 2H), 
7.39–7.12 (m, 3H), 6.94 (s, 2H, br, NH
2
), 3.76 (s, 3H, -OCH
3
), 
3.69 (s, 3H, -OCH
3
), FAB-MS (mNBA): 723 [Ru(bpy)
2
 (3,4- di-
OCH
3
-btsz)]2+(Cl
2
)−; 652 [Ru(bpy)
2
 (3,4-di-OCH
3
-btsz)]2+; 496 
[Ru(bpy) (3,4-di-OCH
3
-btsz)]2+; 413[Ru(bpy)
2
].
Antineoplastic activity
Albino swiss mice (18–20 g body weight) were maintained 
in identical laboratory conditions and given standard food 
pellets (Hindustan Lever Ltd, Bombay, India) and water ad 
libitum. LD
50
 values of the synthesized compounds were 
determined according to the literature38. All compounds 
were dissolved in 10% DMSO solution. The animals were 
divided into 15 groups each containing 12 mice. Group I was 
the vehicle control group (5mL/kg body weight, i.p.) and 
group II was the EAC control group (2 × 106 EAC cells/mouse, 
i.p.). Group III were treated with the standard drug cisplatin 
(2 mg/kg body weight). All the compounds were administered 
(i.p.) at a dose of 2 mg/kg body weight in groups IV–XV, respec-
tively. Mice were treated with the compounds and cisplatin 
daily for 9 days starting 24 h after tumor transplantation. Six 
animals from each group were sacrificed 18 h after the last 
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dose. Ascitic fluid volume and Ascitic cell count parameters 
were noted. Mean survival time (MST) for the remaining six 
mice of each group was noted.
Tumor volume and viable cell count
Ascites volume was noted by taking it in a graduated centri-
fuge tube, and packed cell volume determined by centrifug-
ing at 1000g for 5 min. The viability of ascitic cells was checked 
by Trypan blue (0.4% in normal saline) dye exclusion test 
and the count was taken in a Neubauer counting chamber. 
The effect of the ruthenium complexes on tumor growth was 
monitored by recording the mortality daily, and percentage 
increase in life span (ILS%) was calculated by the following 
formula:
ILS (%) =  [(mean survival of treated group)/(mean survival of 
control group) – 1] × 100
Cytotoxic evaluation
The compounds prepared in the laboratory were evalu-
ated against Molt 4/C
8
, CEM, and L1210 cells by a literature 
procedure39.
Results and discussion
Chemistry
Ligands type r-binh (r-binh = substituted benzyl isonico-
tinyl hydrazones) were prepared by reacting substituted 
benzaldehydes with isoniazid in alcohol at 1:1 molar ratio 
(Scheme 1), and r-btsz (r-btsz = substituted benzyl thiosemi-
carbazones) were prepared by reacting substituted benzal-
dehydes with thiosemicarbazide in alcohol at 1:1 molar ratio 
(Scheme 1). All ligands were confirmed for their purity by 
their melting point, elemental analysis, and other spectral 
studies. Details of the strategy adopted for the synthesis of 
these ruthenium homoleptic compounds are as follows. 
The starting material for synthesis of the compounds was 
cis-bis(1,10- phenanthroline) dichlororuthenium(II)/cis-
bis(2,2’-bipyridine) dichlororuthenium(II). Ruthenium 
trichloride was refluxed in DMF in the presence of 1,10-
phenanthroline/2,2’-bipyridine and in excess of the 
stoichiometric amount, which afforded the final product 
cis-bis(1,10-phenanthroline) dichlororuthenium(II)/cis-
bis(2,2’-bipyridine)dichlororuthenium (II)37 (Scheme 2). The 
third ligand was introduced in alcohol in the presence of a 
nitrogen atmosphere (Scheme 3).
The structures of the ligands, especially r-inh and r-btsz, 
were capable of exhibiting bidentate behavior. There are very 
few cases in which the thiosemicarbazide acts as a monoden-
tate ligand, binding to the metal center through the sulfur 
atom40,41. In the case of r-btsz ligands the chelating mode was 
via the sulfur atom and imine nitrogen by a coordination 
covalent bond. In the case of r-binh ligands a covalent bond 
was formed between the metal ion and oxygen atom and a 
coordinate covalent bond with the imine nitrogen.
The infrared spectra of all ligands and their ruthenium(II) 
compounds were recorded in KBr powder by the diffuse 
reflectance technique, and are reported in their respective 
titles by tentative assignments. The r-btsz ligands showed 
vibrational frequency from 3400 to 3200 cm−1 for NH
2
 and 
N-H stretching, and from 1335 to 1325 cm−1for C=S stretching. 
The r-binh ligands showed vibrational frequency from 3320 
to 3200 cm−1 for N-H stretching and from 1690 to 1670 cm−1 
for C=O stretching.
A comparison of IR spectra of r-btsz ligands and ruthenium 
complexes confirmed coordination to the metal center by the 
sulfur atom and imine nitrogen. Comparing the IR spectra of 
r-binh ligands and ruthenium compounds confirmed coordi-
nation to the metal center by an oxygen atom and imine nitro-
gen. In complexes such as Ru 1–Ru 2, Ru 5–Ru 6, Ru 9–Ru 10, 
coordination occurred via the sulfur and imine nitrogen but 
not with the terminal amine group; this was confirmed by the 
spectra, which indicated no change in vibrational frequency 
of the NH
2
 group between 3400 and 3300 cm−1.
Coordination of ligands (K = r-binh, r-btsz) to ruthenium 
resulted in compounds such as [Ru(S)
2
(K)]2+Cl
2
(Ru 1–Ru 12), 
respectively. These compounds did not possess any C2 axes 
of symmetry. Such a loss of C2 axis of symmetry was seen 
for [Ru(L)
2
(R)]33–35 (where L = 2,2’-bipyridine/1,10-phenan-
throline and R = acetazolamide, 7-iodo-8-hydroxy-quinoline, 
4-substituted thiopicolinanalide, etc.). All compounds had 
well-resolved resonance peaks, which corresponded to four 
HN
SH2N
NH2
N
N
H
O
NH2
H
O
R
Reflux in Alcohol, 3Hrs
H
O
R
Reflux in
Alcohol, 3Hrs
H
NNH
H2N S
R
r-btsz
N
N
H
O
N
R
thiosemicarbazide
isoniazide r-binh
R = 4-OH, 4-CH3, 3,4-di-OCH3
R = 4-OH, 4-CH3, 3,4-di-OCH3
Scheme 1. Preparation of ligands (r-btsz and r-binh).
Ru
N
N
N
N
Cl Cl
S
SRuCl3·xH2O
N2      DMF
"S" Ligand
cis-[Ru(S)2Cl2]
Where S = 2,2'-bipyridine/ 1,10-phenanthroline
Scheme 2. Preparation of cis-[Ru(S)
2
Cl
2
].
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different aromatic ring protons of the two 2,2’-bipyridine/1,10-
phenanthroline ligands and the third ligand.
These compounds showed broad and intense visible bands 
between 340 and 510 nm due to a metal–ligand charge trans-
fer transition (MLCT). In the UV region the bands at 280 and 
310 nm were assigned to 2,2’-bipyridine/1,10-phenanthroline 
ligand p–p* charge transfer transitions. The same transition 
was found in free 2,2’-bipyridine/1,10-phenanthroline at 
270 nm, so that coordination of the ligand resulted in a red 
shift in the transition energy. There were also two shoulders at 
380 and 500 nm, which were, tentatively, attributed to metal–
ligand charge transfer transitions involving 2,2’-bipyridine, 
1,10-phenanthroline, and the third ligand.
In the 1H-NMR spectra of the complexes, there were 
resolved resonance peaks at low field at δ 10.02 (s, br, NH), 
7.68 (s, 1H, O-H). Thus, in the case of Ru 1, there were 25 
resonance peaks (δ 10.03–6.13), and 25 well-resolved peaks 
(δ 10.00–6.34) for Ru 2.
The mass spectra of the complexes confirmed the formulae 
suggested by their molecular ion peaks. The spectrum showed 
numerous peaks representing successive degradation of the 
molecule. FAB mass spectroscopic data clearly suggested 
that mononuclear complexes had been formed in each case, 
the first fragment being due to the [Ru(S)
2
(K)]2+–Cl
2
− ion pair. 
The complex also showed a peak due to the complex cation 
[Ru(S)
2
(K)]2+ and others due to [Ru(S)(K)]2+ and [Ru(S)
2
]2+ 
respectively (where S = 1,10-phenanthroline/2,2’-bipyridine 
and K = r-binh, r-btsz). This type of fragmentation has been 
reported for [Ru(phen)
2
(nmit)]Cl
2
 and [Ru(bpy)
2
(ihqs)]Cl
2
 
(where phen = 1,10-phenanthroline, bpy = 2,2’-bipyridine, 
nmit = N-methyl isatin thiosemicarbazone, ihqs = 7-iodo-8-
hydroxyquinoline-5-sulfonicacid)33. In all cases, the loss of 
chlorine ions was detected where S = 2,2’-bipyridine/1,10-
phenanthroline and K = r-binh, r-btsz. Thus, based on the 
above observations, it is tentatively suggested that Ru(II) 
complexes show an octahedral geometry (Figure 1).
Biological activity and discussion
Results are summarized in Tables 1 and 2 and the pharma-
cological data were analyzed statistically by ANOVA (analysis 
of variance). Statistical significance was considered only 
when p < 0.05 and F > F
critical
. All the complexes were tested for 
their anticancer activity in mice bearing EAC tumors. Ru 6  
was found to increase the life span of the tumor hosts by 
52%, while the remaining ruthenium complexes were able to 
increase the life span in the tumor hosts by 10–38% only. The 
results of the present study clearly demonstrated the tumor 
inhibitory activity of the ruthenium complexes against the 
transplantable murine tumor cell line (Table 1).
The in vitro cytotoxic activity was evaluated for all the 
synthesized ligands and the ruthenium complexes against 
human Molt 4/C
8
 and CEM T-lymphocytes as well as murine 
L1210 cells, and the results are summarized in Table 2. The 
relative potencies between ligands and their ruthenium com-
plexes revealed the importance of ruthenium metal using 
the 4/C
8
 and CEM assays and murine L1210 assay. These 
determinations showed that in comparison to the ligands, 
the ruthenium complexes were more potent.
Ru
N
N
N S
N
N
S
S
K
Ru
N
N
N
N
Cl Cl
S
S
2+
Cl2
Reflux in Alcohol
Ligand r-btsz, N2 atm
Reflux in Alcohol
Ligand r-binh, N2 atm
Ru1-Ru2, Ru5-Ru6, Ru9-Ru10
Ru
N
N
N O
N
N
S
S
K
2+
Cl2
Ru3-Ru4, Ru7-Ru8, Ru11-Ru12
cis-[Ru(S)2Cl2]
Scheme 3. Preparation of tris chelates from cis-[Ru(S)
2
Cl
2
].
Cl2
N N
H
S
NH2
Ru
NN
N
N
R
2+
Cl2
2+
N
N
Ru
NN
N
N
O
N
H
R
Ru 1, Ru 2, Ru 5,
Ru 6, Ru 9, Ru 10
Ru 3, Ru 4, Ru 7,
Ru 8, Ru 11, Ru 12
Figure 1. Structures of the ruthenium(II) complexes, where N = 1,10-
phenanthroline/2,2’-bipyridine, R= 4-OH, 4-CH
3
, 3,4-di-OCH
3
.
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The cytotoxicity data in Table 2 revealed that most ruthe-
nium complexes had significant cytotoxic potencies (IC
50
 
values in the range 0.21–3.1 for Molt 4/C
8
, and 0.75–5.9 µM 
for L1210). On the other hand, for the ligands, the IC
50
 values 
were in excess (84–223 µM against CEM, 96–328 µM for Molt 
4/C
8
, and 64–244 µM for L1210). Of the tested ligands and 
ruthenium complexes, Ru 3 showed cytotoxicity against all 
three cell lines tested in the region of 0.21, 0.24, and 0.78 µM 
for Molt 4/C
8
, CEM, and L1210, respectively. Another com-
plex, Ru 5, showed cytotoxicity against the cell lines tested 
at 0.39 µM for Molt 4/C
8
, 0.48 for CEM, and 0.82 for L1210. 
Yet another complex, Ru 7, showed cytotoxicity against the 
cell lines tested at 0.29 µM for Molt 4/C
8
, 0.16 for CEM, and 
0.75 for L1210. The remaining ruthenium complexes showed 
low-µM values for Molt 4/C
8
 and CEM and higher-µM values 
for L1210. In comparison with the ruthenium complexes, the 
ligands displayed cytotoxicty at higher-µM concentration.
From the results presented in Table 2, it is clear that several 
ruthenium complexes exhibited a marked inhibitory effect on 
the proliferation of tumor cells, with IC
50
 values from as low 
as 0.21 µM for Molt 4/C
8
, 0.16 µM for CEM, and 0.75 µM for 
L1210. Thus, the ruthenium complexes proved inhibitory to 
tumor growth at submicromolar concentration. Their ligands, 
however, were not antitumorally active.
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Table 1. Antineoplastic activity of ruthenium complexes against EAC bearing mice.
Parameter Total body weight (g) Mean survival time (days) ILS% Tumor volume (mL) Viable cells in ascitic fluid (%)
Group I 24.2 ± 0.5 — — — —
Group II 27.8 ± 0.6 21 — 3.4 ± 0.3 94.8 ± 3.8
Group III 19.6 ± 0.5 22 5 — —
Group IV 22.4 ± 0.4 29 38 0.9 ± 0.07 36.2 ± 1.1
Group V 23.2 ± 0.7 26 24 1.1 ± 0.03 43.5 ± 1.4
Group VI 23.7 ± 0.8 25 19 1.4 ± 0.04 45.6 ± 1.2
Group VII 28.4 ± 0.6 28 33 1.0 ± 0.04 38.8 ± 1.7
Group VIII 25.3 ± 0.3 24 14 1.2 ± 0.03 46.9 ± 1.4
Group IX 26.8 ± 0.2 32 52 0.7 ± 0.03 28.4 ± 1.6
Group X 26.4 ± 0.5 26 24 1.1 ± 0.02 43.4 ± 1.3
Group XI 24.2 ± 0.5 25 19 1.4 ± 0.06 45.2 ± 1.4
Group XII 22.9 ± 0.4 28 33 1.0 ± 0.02 38.6 ± 1.8
Group XIII 24.8 ± 0.6 26 24 1.1 ± 0.04 43.8 ± 1.2
Group XIV 22.6 ± 0.8 23 10 1.3 ± 0.06 47.9 ± 1.5
GroupXV 23.8 ± 0.2 25 19 1.9 ± 0.04 45.1 ± 1.3
Note. Values are mean ± SEM. ILS% = [(mean survival of treated group)/(mean survival of control group) – 1] × 100. Group I, vehicle (5 mL/kg); Group II, 
EAC (2 × 106 cells/mouse); Group III, cisplatin (2 mg/kg) + EAC; Group IV, Ru 1; Group IV–Group XV, ruthenium complexes (2 mg/kg) + EAC.
Table 2. Cytotoxic studies of ligands and ruthenium compounds.
Compound
IC
50
a (µM)
L1210 Molt 4/C
8
CEM
4-OH-btsz 244 ± 8 328 ± 12 223 ± 4
4-CH
3
-btsz 186 ± 21 126 ± 34 136 ± 22
3,4-di-OCH
3
-btsz 72 ± 4 88 ± 12 84 ± 33
4-OH-binh 232 ± 12 180 ± 24 163 ± 26
4-CH
3
-binh 94 ± 22 227 ± 13 128 ± 42
3,4-di-OCH
3
-binh 64 ± 32 96 ± 28 202 ± 64
Ru 1 18 ± 4 3.1 ± 1.8 2.9 ± 0.8
Ru 2 32 ± 12 24 ± 0.6 19 ± 5
Ru 3 0.78 ± 0.6 0.21 ± 0.02 0.24 ± 0.21
Ru 4 8.7 ± 0.3 0.65 ± 0.11 0.96 ± 0.53
Ru 5 0.82 ± 0.04 0.39 ± 0.03 0.48 ± 0.16
Ru 6 1.8 ± 0.2 1.2 ± 0.4 0.19 ± 0.14
Ru 7 0.75 ± 0.06 0.29 ± 0.07 0.16 ± 0.09
Ru 8 5.9 ± 1.3 1.4 ± 0.1 2.1 ± 0.2
Ru 9 0.91 ± 0.08 0.26 ± 0.03 0.22 ± 0.02
Ru 10 3.9 ± 1.5 0.92 ± 0.24 2.3 ± 0.5
Ru 11 1.5 ± 0.3 0.36 ± 0.04 1.6 ± 0.4
Ru 12 12 ± 1.4 18 ± 12 10 ± 06
a50% inhibitory concentration, required to inhibit tumor cell proliferation by 50%.
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